Chronic Obstructive Pulmonary Disease Clinical Trial
— FOCuSEdOfficial title:
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
We will conduct a Type I hybrid effectiveness-implementation study to test an integrated telehealth intervention among 400 overweight and obese patients with COPD and OSA. We will include eligible participants receiving primary care at one of five Department of Veterans Affairs (VA) medical centers and their community-based outpatient clinics. We will randomize patients in a 1:1 ratio to the multi-component intervention or "enhanced" usual care, stratifying by age (≥65 vs. < 65) and site. Participants randomized to the intervention will receive an integrated, telehealth-delivered intervention composed of a self-directed lifestyle program and supervised pulmonary rehabilitation. At the end of 3 months, we will offer to enter a recommendation for weight management medications on behalf of eligible intervention participants. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach. For participants randomized to the "enhanced" usual care group, study staff will prompt the patient's primary care provider to refer them to existing weight loss management and pulmonary rehabilitation programs. Follow-up will occur at virtual visits at 3 and 12 months. Our primary effectiveness outcome at 1-year is quality of life measured by the SF-12 Physical Component Summary Score. Secondary effectiveness outcomes will include other measures of quality of life (including sleep related impairment), sleep disturbance, disease severity (COPD exacerbations and respiratory event index for OSA), depression, social support, weight loss and cardiovascular risk. In addition to assessing effectiveness, we will also conduct a concurrent implementation process evaluation using the RE-AIM framework.
Status | Not yet recruiting |
Enrollment | 400 |
Est. completion date | October 1, 2028 |
Est. primary completion date | July 1, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - COPD: Defined by presence of airflow obstruction (FEV1/FVC < 0.70) on post-bronchodilator spirometry - =10 pack year history of tobacco use - Self-reported clinician diagnosis of OSA (or presence of OSA on research HSAT) - BMI = 25 kg/m2 - Symptoms of dyspnea defined by MMRC score of =2 - = 40 years old Exclusion Criteria: - Self-report of weight change >15 lbs. during prior 3 months - Current active weight loss treatment, including: 1) research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS, MOVE!); 2) other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) in the local community; 3) prescription weight loss medication within last 3 months; and scheduled bariatric surgery. - Severe illness from any cause - Diagnosis of bulimia or history of purging behavior - Active enrollment in pulmonary rehabilitation - Safety and/or adherence concerns due to severe physical or mental health issues or life expectancy < 12 months. These include but may not be limited to: unstable cardiac arrhythmias, active or recent (within one month) myocardial infarction, active or recent (within one month) COPD exacerbation, angina not well-controlled with medication, significant musculoskeletal comorbidities or physical infirmities that preclude participation in an exercise program, and the need for supplemental oxygen = 5 lpm at rest or with exertion. - Pregnant, lactating, or planning to become pregnant during the study period - Participation in other intervention studies. - Prisoner - Unable to complete surveys in English |
Country | Name | City | State |
---|---|---|---|
United States | Boise VA Medical Center | Boise | Idaho |
United States | Jesse Brown VA Medical Center | Chicago | Illinois |
United States | Minneapolis VA Health Care System | Minneapolis | Minnesota |
United States | VA Puget Sound Health Care System | Seattle | Washington |
United States | Mann-Grandstaff VA Medical Center | Spokane | Washington |
Lead Sponsor | Collaborator |
---|---|
Seattle Institute for Biomedical and Clinical Research | Patient-Centered Outcomes Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Health-Related Quality of life | Physical Component Score (PCS) of Short Form (SF) - 12 | 1 year | |
Secondary | Sleep-related impairment | Patient-Reported Outcomes Information System (PROMIS) Sleep-Related Impairment (SRI) | 1 year | |
Secondary | Sleep-related impairment | Patient-Reported Outcomes Information System (PROMIS) Sleep-Related Impairment (SRI) | 3 months | |
Secondary | Health-related Quality of Life | Physical Component Score (PCS) of Short Form (SF) - 12 | 3 months | |
Secondary | Health-Related Impairment | Mental Component Score (MCS) of SF-12 | 3 months | |
Secondary | Health-Related Impairment | Mental Component Score (MCS) of SF-12 | 1 year | |
Secondary | Sleep Disturbance | PROMIS Sleep Disturbance (SDA) | 3 months | |
Secondary | Sleep Disturbance | PROMIS Sleep Disturbance (SDA) | 1 year | |
Secondary | Clinical Outcomes | Death or Exacerbations | 3 months | |
Secondary | Clinical Outcomes | Death or Exacerbations | 1 year | |
Secondary | Disease-specific quality of life | COPD Assessment Test (CAT) | 3 months | |
Secondary | Disease-specific quality of life | COPD Assessment Test (CAT) | 1 year | |
Secondary | Weight Loss | Total (kg) | 3 months | |
Secondary | Weight Loss | Total (kg) | 1 year | |
Secondary | Clinically Significant Weight Loss | 5% weight loss met | 3 months | |
Secondary | Clinically Significant Weight Loss | 5% weight loss met | 1 year | |
Secondary | Cardiovascular risk | Framingham risk score | 3 months | |
Secondary | Cardiovascular risk | Framingham risk score | 1 year | |
Secondary | Social Support | Social Support for diet and exercise scales | 3 months | |
Secondary | Social Support | Social Support for diet and exercise scales | 1 year | |
Secondary | Depression | PHQ-8 Depression scale | 3 months | |
Secondary | Depression | PHQ-8 Depression scale | 1 year | |
Secondary | Strength and endurance | 30 second chair stand | 3 months | |
Secondary | Strength and endurance | 30 second chair stand | 1 year | |
Secondary | OSA Severity | Home-Sleep Apnea Testing: Respiratory Event Index | 1 Year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|